A clinical trial of Novartis’s Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday. Novartis said Cosentyx, when used to treat active psoriatic arthritis, “narrowly missed statistical significance for superiority” versus Humira, a drug made by AbbVie. “While Cosentyx narrowly missed statistical significance for superiority…. it showed numerically higher results versus Humira,” Novartis said following the results of a head-to-head trial. …read more
Source:: Yahoo Finance
